Researchers have identified a promising therapeutic approach to combat intervertebral disc degeneration (IDD) through the administration of the growth factor FGF21, which upregulates the sirtuin SIRT1 in spinal disc cells. This mechanism enhances mitophagy, the process responsible for the removal of damaged mitochondria, thereby addressing cellular senescence—a key contributor to disc degeneration. The findings, published in Aging Cell, were validated in a rat model of IDD, where FGF21 treatment resulted in significant improvements in disc morphology and cellular health.

The study highlights the critical role of mitophagy in maintaining cellular integrity, particularly in the context of aging and degenerative diseases. In the induced IDD model, FGF21 administration led to a marked reduction in senescence biomarkers such as p16, p21, and SA-β-gal, while also restoring mitochondrial function and ATP production. Importantly, the researchers demonstrated that the activation of the PINK1-Parkin pathway was essential for FGF21’s effects on mitophagy, revealing a specific signaling cascade that could be targeted for therapeutic development.

This research shifts the paradigm in IDD treatment by emphasizing the potential of targeting mitochondrial health and cellular senescence through growth factors like FGF21. The findings suggest that future drug development could focus on enhancing mitophagy and sirtuin activity as a strategy for delaying or reversing disc degeneration. Given the correlation between FGF21 levels and age-related symptoms in humans, further exploration of this pathway could open new avenues for clinical interventions in age-associated spinal disorders.

Source: lifespan.io